Is venture capital a necessity for start-ups?
This article was originally published in Clinica
For most new medtech companies, venture capital appears to be the most obvious way of garnering the necessary start-up funds to build a solid business. However, according to Dr Ian Cumming, CEO of Welsh start-up Ovasort, a company focused on developing high-volume cell separation technology, this is not always the best way to lever a start-up into financial growth. Ovasort itself is an example of a firm that has prospered without the crutch of venture capital. The company, located at Cardiff University's MediCentre for burgeoning medical and healthcare companies, is "a company without a product" according to Dr Cumming. Ovasort owns a patent for assisting with the process of discovering proteins on the surfaces of cells. The company is currently using this patent to develop a low-cost sperm separation kit for distinguishing between X- and Y-chromosome bearing cells for the artificial cattle insemination market and is also looking to diversify into the cancer research and diagnostics sector.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.